Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation
N Yang, Z Fan, S Sun, X Hu, Y Mao, C Jia, X Cai… - European Journal of …, 2023 - Elsevier
Although several covalent KRAS G12C inhibitors have made great progress in the treatment
of KRAS G12C-mutant cancer, their clinical applications are limited by adaptive resistance …
of KRAS G12C-mutant cancer, their clinical applications are limited by adaptive resistance …
Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation
N Yang, Z Fan, S Sun, X Hu, Y Mao, C Jia… - European journal of … - pubmed.ncbi.nlm.nih.gov
Although several covalent KRAS G12C inhibitors have made great progress in the treatment
of KRAS G12C-mutant cancer, their clinical applications are limited by adaptive resistance …
of KRAS G12C-mutant cancer, their clinical applications are limited by adaptive resistance …
Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation.
N Yang, Z Fan, S Sun, X Hu, Y Mao, C Jia… - European Journal of …, 2023 - europepmc.org
Although several covalent KRAS G12C inhibitors have made great progress in the treatment
of KRAS G12C-mutant cancer, their clinical applications are limited by adaptive resistance …
of KRAS G12C-mutant cancer, their clinical applications are limited by adaptive resistance …